

Department of Neurology Faculty Papers

Department of Neurology

7-10-2021

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis

lyad Alnahhas

Mouaz Alsawas

Appaji Rayi

Joshua D Palmer

Raju Raval

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp

Part of the Neurology Commons, and the Oncology Commons Let us know how access to this document benefits you

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

lyad Alnahhas, Mouaz Alsawas, Appaji Rayi, Joshua D Palmer, Raju Raval, Shirley Ong, Pierre Giglio, Mohammad Hassan Murad, and Vinay Puduvalli 3(1), 1–1, 2021 | https://doi.org/10.1093/noajnl/vdab095 | Advance Access date 10 July 2021

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis

lyad Alnahhas, Mouaz Alsawas, Appaji Rayi, Joshua D. Palmer, Raju Raval, Shirley Ong, Pierre Giglio, Mohammad Hassan Murad, and Vinay Puduvalli

Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA (A.R., S.O., P.G., V.P.); Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA (M.A., M.H.M.); Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA (J.D.P., R.R.); Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA (I.A.)

Corresponding Author: Iyad Alnahhas, MD, MSc, Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson Universit, 901 Walnut St. Room 310G. Philadelphia, PA 19107, USA (iyad.alnahhas@gmail.com).

In the originally published version of this manuscript, there was an error in co-author Mohammad Hassan Murad's name. The full name should read: "Mohammad Hassan Murad" instead of "Hassan M. Murad". This error has now been corrected online.

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com